Journey Medical

Yahoo Finance • 2 days ago

Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand

Earnings Call Insights: Journey Medical Corporation (DERM) Q4 2025 MANAGEMENT VIEW * Claude Maraoui, Founder, President, CEO & Director, described 2025 as a milestone year, highlighting the successful launch of Emrosi, Journey’s intern... Full story

Yahoo Finance • 10 days ago

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Dru... Full story

Yahoo Finance • 4 months ago

What Makes Journey Medical Corporation (DERM) a Good Investment?

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the... Full story

Yahoo Finance • 4 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Third quarter 2025 net revenues were$17.6million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the finan... Full story

Yahoo Finance • 5 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug... Full story

Yahoo Finance • 5 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults DFD-29 de... Full story

Yahoo Finance • 6 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug... Full story

Yahoo Finance • 6 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 6 months ago

Summers Value Partners’ Update on Journey Medical (DERM)

Summers Value Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of -1.8% net in Q2 2025, trailing the... Full story

Yahoo Finance • 6 months ago

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story

Yahoo Finance • 7 months ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Dru... Full story

Yahoo Finance • 7 months ago

Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream

MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies co... Full story

Yahoo Finance • 7 months ago

Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream

MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies co... Full story

Yahoo Finance • 7 months ago

Journey Medical Corporation to Present at the Emerging Growth Conference

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-a... Full story

Yahoo Finance • 7 months ago

What's going on in today's pre-market session

As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE CO... Full story

Yahoo Finance • 7 months ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Second quarter 2025 revenues were$15.0million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call to... Full story

Yahoo Finance • 8 months ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketi... Full story

Yahoo Finance • 8 months ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and... Full story

Yahoo Finance • 8 months ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE... Full story

Yahoo Finance • 9 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketi... Full story